HK1025500A1 - Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases - Google Patents

Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases

Info

Publication number
HK1025500A1
HK1025500A1 HK00101942A HK00101942A HK1025500A1 HK 1025500 A1 HK1025500 A1 HK 1025500A1 HK 00101942 A HK00101942 A HK 00101942A HK 00101942 A HK00101942 A HK 00101942A HK 1025500 A1 HK1025500 A1 HK 1025500A1
Authority
HK
Hong Kong
Prior art keywords
lymphotoxin
antibodies
treatment
immunological diseases
therapeutic agents
Prior art date
Application number
HK00101942A
Other languages
English (en)
Inventor
Jeffery Browning
Paula Susan Hochman
Paul D Rennert
Fabienne Mackay
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of HK1025500A1 publication Critical patent/HK1025500A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK00101942A 1996-10-25 2000-04-10 Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases HK1025500A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2906096P 1996-10-25 1996-10-25
PCT/US1997/019436 WO1998017313A2 (en) 1996-10-25 1997-10-24 Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases

Publications (1)

Publication Number Publication Date
HK1025500A1 true HK1025500A1 (en) 2000-11-17

Family

ID=21847003

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00101942A HK1025500A1 (en) 1996-10-25 2000-04-10 Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases

Country Status (26)

Country Link
EP (1) EP0954333B1 (pl)
JP (1) JP4299887B2 (pl)
KR (1) KR100584704B1 (pl)
CN (2) CN101239186A (pl)
AT (1) ATE331531T1 (pl)
AU (1) AU726357B2 (pl)
BG (1) BG63565B1 (pl)
BR (1) BR9712670A (pl)
CA (1) CA2269614A1 (pl)
CZ (1) CZ142899A3 (pl)
DE (1) DE69736244T2 (pl)
DK (1) DK0954333T3 (pl)
EA (1) EA002983B1 (pl)
EE (1) EE05213B1 (pl)
ES (1) ES2268727T3 (pl)
HK (1) HK1025500A1 (pl)
HU (1) HU226467B1 (pl)
IL (1) IL129527A (pl)
IS (1) IS5031A (pl)
NO (1) NO328540B1 (pl)
NZ (1) NZ335353A (pl)
PL (1) PL190617B1 (pl)
PT (1) PT954333E (pl)
SK (1) SK55399A3 (pl)
TR (1) TR199901636T2 (pl)
WO (1) WO1998017313A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
DE69931944T2 (de) * 1998-10-09 2007-02-08 Biogen Idec Ma Inc., Cambridge Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
SK18852001A3 (sk) * 1999-06-28 2002-12-03 Basf Aktiengesellschaft Použitie látok potláčajúcich LTBR-sprostredkovanú aktiváciu
DE19939653A1 (de) * 1999-08-13 2001-02-22 Thomas Huenig Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
ATE483807T1 (de) * 2000-04-12 2010-10-15 Jolla Inst Allergy Immunolog Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen
BR0317573A (pt) * 2002-12-20 2005-11-22 Biogen Idec Inc Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos
NZ576032A (en) 2006-10-12 2012-03-30 Genentech Inc Antibodies to lymphotoxin-alpha
MX2009004134A (es) 2006-10-20 2009-08-12 Biogen Idec Inc Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble.
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CA2763439A1 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins
EP3807401A1 (en) * 2018-06-15 2021-04-21 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
KR102360196B1 (ko) 2019-10-30 2022-02-08 주식회사 친환경테크 다용도 시트 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507201A (ja) * 1992-12-04 1996-08-06 バイオジェン，インコーポレイテッド リンホトキシン‐β、リンホトキシン‐β複合体、それらの薬学的な調製物および治療への使用
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

Also Published As

Publication number Publication date
IL129527A0 (en) 2000-02-29
ATE331531T1 (de) 2006-07-15
WO1998017313A3 (en) 1998-07-30
BG63565B1 (bg) 2002-05-31
PT954333E (pt) 2006-10-31
JP2001502697A (ja) 2001-02-27
HU226467B1 (en) 2008-12-29
IS5031A (is) 1999-04-21
BR9712670A (pt) 1999-10-19
CN101239186A (zh) 2008-08-13
CN1237910A (zh) 1999-12-08
EE05213B1 (et) 2009-10-15
SK55399A3 (en) 2000-10-09
NZ335353A (en) 2000-09-29
EP0954333B1 (en) 2006-06-28
CA2269614A1 (en) 1998-04-30
CZ142899A3 (cs) 1999-07-14
HUP9904516A3 (en) 2002-09-30
AU5089698A (en) 1998-05-15
KR20000052800A (ko) 2000-08-25
DK0954333T3 (da) 2006-10-23
AU726357B2 (en) 2000-11-02
ES2268727T3 (es) 2007-03-16
EA199900409A1 (ru) 2000-02-28
IL129527A (en) 2006-12-10
NO991926D0 (no) 1999-04-22
PL332972A1 (en) 1999-10-25
NO328540B1 (no) 2010-03-15
WO1998017313A2 (en) 1998-04-30
KR100584704B1 (ko) 2006-05-30
EA002983B1 (ru) 2002-12-26
PL190617B1 (pl) 2005-12-30
DE69736244T2 (de) 2007-05-31
JP4299887B2 (ja) 2009-07-22
HUP9904516A2 (hu) 2000-05-28
EP0954333A2 (en) 1999-11-10
NO991926L (no) 1999-06-25
TR199901636T2 (xx) 1999-09-21
DE69736244D1 (de) 2006-08-10
CN100382844C (zh) 2008-04-23
BG103416A (en) 2000-01-31
EE9900146A (et) 1999-12-15

Similar Documents

Publication Publication Date Title
HK1025500A1 (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
HUP9802483A3 (en) Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies, as therapeutic agents for the treatment of immunological disease
BG109311A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNFAL, AND HIS APPLICATION
EP0959896A4 (en) COMPOSITIONS BASED ON THE HUMAN THYROTROPIN RECEPTOR AND THEIR USE
FI963101A0 (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
FI933862A0 (fi) Loesliga ligander foer cd40
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
NO963168D0 (no) Immunstimulatoriske monoklonale antistoffer
GR3025698T3 (en) NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES.
PT939809E (pt) Ligandos do receptor de tie-2 (ligando 3 de tie e ligando 4 de tie) e suas utilizacoes
CA2070182A1 (en) Chimeric immunoglobulin for cd4 receptors
EP1723967A3 (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
Predy Characterization of novel antigens, detected using monoclonal antibodies raised against tissue from the central nervous system of multiple sclerosis patients
AU3723397A (en) Therapeutic multispecific compounds comprised of anti-fcalpha receptor antibodies

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131024